New Feature Coming Soon, Stay Tuned!
Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Annexin Pharmaceuticals AB (publ), a biotechnology company, develops drug candidates for the treatment of various cardiovascular diseases. The company develops ANXV, a human recombinant protein. It offers Annexin A5 to protect and repair blood vessels and counteract inflammation. The company was founded in 2014 and is based in Stockholm, Sweden.
STO
Unprofitable
EPS improving
Unprofitable
EPS improving
0.40Â ( 1.42%)
Relative Strenght
Volume Buzz
-88%
Earning Acce
No
Dist 52w H.
69%